deepc Expands Prostate MRI Portfolio with QP-Prostate® Supporting Earlier and More Reliable Prostate Cancer Detection

Prostate MRI has become an essential tool in the early detection and management of prostate cancer. As scan volumes increase, radiology teams face growing pressure to deliver timely and accurate interpretations across complex imaging data. This challenge can lead to delays, inconsistent assessments, and difficulty maintaining high diagnostic accuracy across readers and clinical sites.

deepc has partnered with Quibim to integrate QP-Prostate® into deepcOS®. QP-Prostate® automates image quality assessment, prostate segmentation, lesion detection, and structured reporting. By providing clinical insights, including an AI-QUAL™ image quality score based on PI-QUAL v2 guidelines, precise prostate volumetry, and detection of suspicious lesions with confidence-based scoring, it helps reduce manual effort and enables more consistent, reproducible assessments across readers and clinical settings. Its lesion detection algorithm, trained on biopsy-confirmed cases, supports radiologists in achieving higher accuracy for clinically significant prostate lesions.

The solution integrates seamlessly into existing PACS environments and supports continuity from imaging through to intervention and treatment planning. By embedding these capabilities directly into the radiologist’s workflow, it enables consistent analysis without adding operational complexity.

Delivered through deepcOS®, QP-Prostate® can be evaluated, deployed, and monitored within a governed environment. Healthcare institutions can assess performance on local data and manage the solution alongside other AI solutions, supporting controlled and scalable adoption across clinical settings.

QP-Prostate® has been validated in several independent studies, including work at Massachusetts General Hospital, demonstrating improved sensitivity when used alongside expert radiologists, with increases of up to 10% in radiologist sensitivity. The solution holds CE marking, UKCA marking, and FDA 510(k) clearance across all three major markets.

deepc’s prostate MRI portfolio is built on clinical specificity. QP-Prostate® extends this approach by addressing variability in image quality and interpretation, supporting more consistent and structured prostate MRI assessment as volumes continue to grow.

For departments managing high prostate MRI volumes, more consistent and faster interpretation aligned with PI-RADS is now available across readers, sites, and workflows through deepcOS®.